Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A1 | P46059 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498835 | 1.00 | SLC15A1 (0.66) | SLC15A1ACEMMELTA4HALPI | |
| SCHEMBL18381240 | 0.91 | LTA4H (0.68) | SLC15A1ACEMMELTA4H | |
| SCHEMBL7865260 | 0.91 | LTA4H (0.68) | SLC15A1ACEMMELTA4H | |
| SCHEMBL21010316 | 0.90 | SLC15A1 (0.64) | SLC15A1LTA4HALPIPKMPTGS1 | |
| SCHEMBL16116048 | 0.88 | SLC7A5 (0.58) | SLC15A1ACEMMESLC7A5MMEL1 | |
| SCHEMBL28035872 | 0.88 | SLC7A5 (0.58) | SLC15A1ACEMMESLC7A5MMEL1 | |
| SCHEMBL18375234 | 0.87 | ALPI (0.59) | SLC15A1LTA4HALPIPKMPTGS1 | |
| SCHEMBL11254327 | 0.87 | ALPI (0.59) | SLC15A1LTA4HALPIPKMPTGS1 | |
| SCHEMBL9113781 | 0.87 | ALPI (0.59) | SLC15A1LTA4HALPIPKMPTGS1 | |
| SCHEMBL16559587 | 0.85 | ALPI (0.58) | LTA4HALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090625-B1 | Topical composition for the skin and use thereof | KAO CORP (JP) | 2004-12-22 | — | — | EP | claimed |
| US-20030087833-A1 | Topical composition for skin | KAO CORPORATION (JP) | 2003-05-08 | — | — | US | claimed |
| US-6489291-B1 | Topical composition for skin | KAO CORPORATION (JP) | 2002-12-03 | — | — | US | claimed |
| EP-1090625-A2 | Topical composition for the skin and use thereof | Kao Corporation (JP) | 2001-04-11 | — | — | EP | claimed |
| US-7189708-B2 | Topical composition for skin | KAO CORPORATION (JP) | 2007-03-13 | — | — | US | disclosed |
| EP-1090625-B1 | Topical composition for the skin and use thereof | KAO CORP (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20030087833-A1 | Topical composition for skin | KAO CORPORATION (JP) | 2003-05-08 | — | — | US | disclosed |
| US-6489291-B1 | Topical composition for skin | KAO CORPORATION (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1090625-A2 | Topical composition for the skin and use thereof | Kao Corporation (JP) | 2001-04-11 | — | — | EP | disclosed |
| US-4963539-A | TREATING HEART FAILURE, PAIN OR DIARRHEA | E. R. SQUIBB & SONS, INC. (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0306879-A2 | Phosphonate and phosphonamide endopeptidase inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087833-A1 | Topical composition for skin | CUTA, SLC38A7, CCR8 | SLC15A1 197/4885ACE 1354/4885MME 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.